Physician profile
Akira Yamamoto
NPI 1669769386
$3,217.92
in general payments reported to CMS, 2019-2025
30 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $429 · 2021: $1,211 · 2022: $166 · 2023: $218 · 2024: $73.13 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $486.22 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $446.40 | 2020-2024 | Prolaris |
| Endo Pharmaceuticals INC. | $248.86 | 2019-2021 | |
| Janssen Biotech, INC. | $247.98 | 2019-2025 | Erleada |
| Antares Pharma, INC. | $201.73 | 2019-2025 | Xyosted |
| Neotract INC. | $165.89 | 2019 | |
| Dendreon Pharmaceuticals LLC | $140.45 | 2019-2021 | |
| Boston Scientific Corporation | $133.02 | 2019-2025 | Axonics |
| Procept Biorobotics Corporation | $124.99 | 2021 | |
| Sumitomo Pharma America, INC. | $94.92 | 2025 | Gemtesa |
| Myovant Sciences INC. | $92.88 | 2021-2022 | |
| Teleflex LLC | $77.93 | 2025 | Barrigel, Urolift |
| Medtronic, INC. | $76.25 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $73.92 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.56 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58.24 | 2019-2025 | |
| Clarus Therapeutics INC. | $55.84 | 2021 | |
| Ferring Pharmaceuticals INC. | $54.23 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $49.18 | 2020-2021 | |
| Amgen INC. | $42.56 | 2019 | |
| Aytu Biopharma, INC. | $39.20 | 2019 | |
| Urovant Sciences INC | $37.08 | 2021-2022 | |
| Blue Earth Diagnostics | $36.56 | 2019-2021 | |
| Mission Pharmacal Company | $33.10 | 2019-2021 | |
| Metuchen Pharmaceuticals | $29.63 | 2019-2020 | |
| Pfizer INC. | $27.48 | 2019-2021 | |
| Acerus Pharmaceuticals Corporation | $23.59 | 2020 | |
| Allergan, INC. | $17.22 | 2021 | |
| Coloplast Corp | $16.81 | 2021 | |
| Rochester Medical Corporation | $16.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akira Yamamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.